Tislelizumab plus cetuximab and irinotecan in patients with previously treated MSS and RAS wild-type advanced colorectal cancer
Release date:
2024-06-01
Description:
This is a single-arm, open-label, phase II study to evaluate the efficacy and safety of tislelizumab in combination with cetuximab plus irinotecan for patients with relapsed or refractory colorectal cancer with RAS wild-type. Patients with RAS wild-type colorectal cancer who had failed at least 2 prior lines of systematic therapy including chemotherapy (oxaliplatin, irinotecan, fluoropyrimidines) with or without targeted agents (cetuximab, bevacizumab) will be recruited in this study. NGS and immune-related proteins test in blood samples obtained before treatment, 4 weeks after the first administration, first assessment at 8 weeks, and at progression aim to assess exploratory predictive biomarkers.
For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.
This is a single-arm, open-label, phase II study to evaluate the efficacy and safety of tislelizumab in combination with cetuximab plus irinotecan for patients with relapsed or refractory colorectal cancer with RAS wild-type. Patients with RAS wild-type colorectal cancer who had failed at least 2 prior lines of systematic therapy including chemotherapy (oxaliplatin, irinotecan, fluoropyrimidines) with or without targeted agents (cetuximab, bevacizumab) will be recruited in this study. NGS and immune-related proteins test in blood samples obtained before treatment, 4 weeks after the first administration, first assessment at 8 weeks, and at progression aim to assess exploratory predictive biomarkers.
Organization: Company Name: Genecast Biotechnology Co., Ltd
Submission date: 2023-07-10
Requests: -
Aspera Command Line
You need to install the Aspera Connect plugin before uploading your files. If you dont have Aspera Connect plugin installed in your computer, please Download Aspera Connectand install it first.
[path/to/ascp]: Microsoft Windows: C:\Program Files\Aspera\Aspera Connect\bin\ascp.exe or
c:\users\[username]\AppData\Local\Programs\Aspera\Aspera Connect\bin\ascp.exe
Mac OS X: /Applications/Aspera/Connect.app/Contents/Resources/ascp (for admin's installation) or
/Users/[username]/Applications/Aspera/Connect.app/Contents/Resources/ascp (for non-admin's installation)
Linux: /opt/aspera/bin/ascp or
/home/[username]/aspera/connect/bin/ascp
[path/to/key/file] must be an absolute path, e.g.: /home/keys/aspera.openssh
[path/to/folder/containing/files] needs to specify the local folder that contains all the files to upload.
HRA005098.xlsx